<DOC>
	<DOCNO>NCT01770353</DOCNO>
	<brief_summary>This Phase I Pilot study understand biodistribution MM-398 determine feasibility use Ferumoxytol tumor image agent .</brief_summary>
	<brief_title>Pilot Study Determine Biodistribution MM-398 Feasibility Ferumoxytol Tumor Imaging Agent</brief_title>
	<detailed_description>This study conduct two phase . The pilot phase trial close . The expansion phase trial currently open enrollment . Pilot Phase : This study enroll approximately 12 patient , 20 total Pilot Phase 30 patient Expansion Phase . The first three patient enrol solid tumor type ; however subsequent patient must NSCLC , CRC , TNBC , ER/PR positive breast cancer , pancreatic cancer , ovarian cancer , gastric cancer , gastro-oesophageal junction adenocarcinoma head neck cancer . No three patient ER/PR positive breast cancer enrol Pilot Phase similar restriction may place tumor type ensure heterogeneous population . Expansion Phase : The expansion enroll patient advance metastatic breast cancer three cohort : Cohort 1 : ER and/or PR-positive breast cancer Cohort 2 : TNBC Cohort 3 : BC active brain metastasis</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Pathologically confirm diagnosis solid tumor , CRC , TNBC , ER/PR Breast Cancer , NSCLC , Pancreatic Cancer , Ovarian Cancer , Gastric Cancer , GEJ adenocarcinoma , Head Neck Cancer Metastatic disease ECOG Performance Status 0 2 Adequate bone marrow , hepatic renal function Normal ECG 18 year age Able understand sign inform consent Expansion Phase Additional Criteria : The follow invasive breast cancer tumor subtypes require : Cohort 1 : hormone receptor positive breast cancer patient ERpositive and/or PRpositive tumor define ≥1 % tumor nuclei immunoreactive ER and/or PR HER2 negative Cohort 2 : triple negative breast cancer ( TNBC ) patient ERnegative , PRnegative tumor define &lt; 1 % tumor nuclei immunoreactive ER PR HER2 negative Cohort 3 : Any subtype metastatic breast cancer active brain metastasis Documented metastatic disease least two radiologically measurable lesion define RECIST v1.1 ( except Cohort 3 , see inclusion criterion ) Received least one cytotoxic therapy metastatic setting , exception TNBC patient progress within 12 month adjuvant therapy Received ≤ 3 prior line chemotherapy metastatic setting ( limit prior line hormonal therapy Cohort 1 ) At least one lesion amenable multiple pas core biopsy ( exception : Cohort 3 patient ) Expansion Phase Cohort 3 additional inclusion criterion : Radiographic evidence new progressive brain metastasis prior radiation therapy least one brain metastasis measure ≥ 1 cm long diameter gadoliniumenhanced MRI ( note : progressive brain lesion require meet RECIST criterion order eligible ; extracranial metastatic disease also allow ) Active CNS metastasis ( applies pilot phase expansion phase cohort 1 2 ) Clinically significant GI disorder Prior irinotecan bevacizumab therapy within last 6 month Known hypersensitivity MM398 ferumoxytol Inability undergo MRI Active infection Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>Triple Negative Breast Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>MM-398</keyword>
	<keyword>nanoliposomal irinotecan</keyword>
	<keyword>Ferumoxytol</keyword>
	<keyword>ER/PR positive Breast Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Gastro-Esophageal Junction Adenocarcinoma</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>TNBC</keyword>
</DOC>